InVivo Therapeutics Holdings Corporation NVIV
Day range unavailable
52-week range unavailable
- Market cap
- 995.92K
- Shares out
- 3.11M
- Forward P/E
- -0.03
- Beta
- 0.66
- Earnings date
- Feb 14, 2024
Key statistics
- Enterprise value
- -7.59M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.11
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -7.03M
- Total cash
- 8.58M
- Total debt
- 0
- Return on equity
- -98.11%
- Short % of float
- 0.64%
- 50-day average
- 0.605553
- 200-day average
- 0.98865
Analyst view
- Strong buy1
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 14, 2024
Expected Feb 14, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 14, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Nov 8, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
| Oct 2, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
| Nov 7, 2022 | Sep 1, 2022 | 0.00 | — | — | — |
About InVivo Therapeutics Holdings Corporation
InVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. On February 1, 2024, InVivo Therapeutics Holdings Corp. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. It is in joint administration with InVivo Therapeutics Corporation.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- invivotherapeutics.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on NVIV — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHRISTOPHER RICHARD C | Chief Financial Officer | Purchase | Mar 9, 2020 | 5,220 |
| FOOSE BRICE | Beneficial Owner of more than 10% of a Class of Security | Sale | Feb 5, 2023 | 0 |
| JOSEPH TAMARA L | General Counsel | Stock Award(Grant) | Dec 30, 2015 | 17,027 |
| LORIANNE MASUOKA K | Officer | Stock Award(Grant) | Dec 30, 2015 | 265 |
| MCALLISTER STEVEN F | Chief Financial Officer | Stock Award(Grant) | Dec 30, 2015 | 19,160 |
| MERRIFIELD C ANN | Director | Purchase | Mar 9, 2020 | 3,639 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 1.12% | 34,714 | 46.86K | Jun 29, 2023 |
| Vanguard Group Inc | 0.85% | 26,246 | 35.43K | Jun 29, 2023 |
| Renaissance Technologies, LLC | 0.56% | 17,266 | 23.31K | Jun 29, 2023 |
| Geode Capital Management, LLC | 0.36% | 11,169 | 15.08K | Jun 29, 2023 |
| Tower Research Capital LLC (TRC) | 0.24% | 7,391 | 9.98K | Jun 29, 2023 |
| Morgan Stanley | 0.01% | 270 | 364 | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.85% | 26,246 | 35.43K | Jun 29, 2023 |
| Fidelity Extended Market Index Fund | 0.22% | 6,721 | 8.80K | May 30, 2023 |
| Fidelity Series Total Market Index Fund | 0.08% | 2,425 | 3.18K | May 30, 2023 |
| Fidelity NASDAQ Composite Index Fund | 0.06% | 1,757 | 2.30K | May 30, 2023 |